Core Viewpoint - The company has received marketing approvals for its injectable drugs in the Netherlands and Saudi Arabia, enhancing its international market presence and product pipeline [1] Group 1: Product Approvals - The company's subsidiary Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. have recently obtained marketing licenses from the Dutch Medicines and Health Products Regulatory Authority and the Saudi Food and Drug Authority for injectable Parecoxib Sodium [1] - Injectable Parecoxib Sodium is indicated for the treatment of short-term postoperative pain in adults, which expands the company's product offerings in the pain management segment [1] - Injectable Pemetrexed Disodium, another product, is approved for use in chemotherapy for unresectable malignant pleural mesothelioma and locally advanced or metastatic lung cancer, enhancing the company's oncology portfolio [1] Group 2: Market Expansion - The approvals for injectable Parecoxib Sodium and injectable Pemetrexed Disodium are expected to enrich the company's international product pipeline, improve its brand image, and facilitate the continuous expansion of its international business [1]

四川汇宇制药股份有限公司 证券代码：688553 证券简称：汇宇制药 公告编号：2025-059 二、药品的其他相关情况 （一）注射用帕瑞昔布钠 关于自愿披露公司产品获得境外上市许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"）子公司 Seacross Pharma (Europe) Ltd.和 Seacross Pharmaceuticals Ltd.近期收到荷兰国家药品和保健品安 全局和沙特阿拉伯健康产品监管局分别核准签发的公司产品注射用帕瑞昔布钠、 注射用培美曲塞二钠的上市许可。现将相关情况公告如下： 一、公司产品获得境外上市许可情况 | 序号 | 产品名称 | 剂型 | 规格 | 上市许可号 | 发证国家 | | --- | --- | --- | --- | --- | --- | | 1 | 注射用帕瑞昔布钠 | 注射剂 | 40mg； | RVG 128196 | 荷兰 | | 2 | 注射用培美曲塞二钠 | 注射剂 | 500mg； | 12052573 ...

Core Viewpoint - Sichuan Huiyu Pharmaceutical Co., Ltd. announced that its subsidiary has received marketing approvals for injectable Parecoxib Sodium and injectable Pemetrexed Disodium from the drug regulatory authorities in the Netherlands and Saudi Arabia respectively [1] Group 1: Product Approvals - Injectable Parecoxib Sodium is indicated for short-term pain management in adults post-surgery and has already been approved in the UK and the Netherlands, with an application submitted in Germany [1] - Injectable Pemetrexed Disodium is used for the treatment of related cancers and has been approved in 14 countries, with applications submitted in 10 additional countries and regions [1] Group 2: Strategic Implications - The recent approvals are expected to enrich the international pipeline and enhance the brand image of the company [1] - However, future sales remain uncertain, and the short-term impact on performance is not expected to be significant [1]

Core Viewpoint - The company has received marketing approvals for its products from regulatory authorities in the Netherlands and Saudi Arabia, enhancing its international market presence and product pipeline [1] Group 1: Product Approvals - Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd., subsidiaries of the company, have obtained marketing licenses for injectable Parecoxib Sodium and injectable Pemetrexed Disodium [1] - Injectable Parecoxib Sodium is indicated for the treatment of short-term postoperative pain in adults [1] - Injectable Pemetrexed Disodium, in combination with Cisplatin, is approved for first-line treatment of unresectable malignant pleural mesothelioma and locally advanced or metastatic lung cancer (primarily non-squamous) [1] Group 2: Market Impact - The approvals are expected to enrich the company's product pipeline in international markets [1] - These developments will enhance the company's brand image and facilitate the continuous expansion of its international business [1]

Core Viewpoint - The company has received marketing approvals for its injectable products, Parecoxib Sodium and Pemetrexed Disodium, from regulatory authorities in the Netherlands and Saudi Arabia, enhancing its international market presence and brand image [1] Group 1 - The company's subsidiary, Seacross Pharma (Europe) Ltd., and Seacross Pharmaceuticals Ltd. have obtained marketing licenses for injectable Parecoxib Sodium and Pemetrexed Disodium [1] - The approvals from the Dutch Medicines and Health Products Regulatory Authority and the Saudi Health Products Regulatory Authority signify a strategic expansion into international markets [1] - The successful launch of these products is expected to enrich the company's product pipeline and support sustainable development in international markets [1]

Core Viewpoint - The company, Huyou Pharmaceutical (688553), announced that its subsidiaries, Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd., have received marketing approvals for their products, injectable Parecoxib Sodium and injectable Pemetrexed Disodium, from the Dutch Medicines and Healthcare Products Regulatory Agency and the Saudi Arabian Health Products Regulatory Authority [1]. Group 1 - The company has successfully obtained marketing licenses for two injectable products [1] - The approvals were granted by regulatory authorities in the Netherlands and Saudi Arabia [1] - This development may enhance the company's market presence in Europe and the Middle East [1]

Core Viewpoint - The company has received marketing approvals for its injectable products, Parecoxib Sodium and Pemetrexed Disodium, from regulatory authorities in the Netherlands and Saudi Arabia, enhancing its international market presence and product pipeline [1] Group 1: Regulatory Approvals - The company's subsidiary, Seacross Pharma (Europe) Ltd., and Seacross Pharmaceuticals Ltd. have obtained marketing licenses for injectable Parecoxib Sodium and injectable Pemetrexed Disodium from the Dutch Medicines and Medical Devices Authority and the Saudi Food and Drug Authority [1] Group 2: Market Impact - The approvals are expected to enrich the company's product pipeline in international markets, improve its brand image, and facilitate the ongoing expansion of its international business [1] - The developments lay a solid foundation for the sustainable growth of the company in international markets [1]

Market Overview - The recombinant protein sector experienced a decline of 1.14%, ranking among the top losers in the concept sector as of the market close on August 12 [1] - Notable stocks within this sector that saw significant declines include HaiTe Bio, Kexing Pharmaceutical, and Huiyu Pharmaceutical, while 13 stocks recorded gains, with *ST WanFang, Zhenghai Bio, and Huabei Pharmaceutical leading the increases at 3.42%, 2.66%, and 2.08% respectively [1] Capital Flow - The recombinant protein sector faced a net outflow of 484 million yuan from major funds, with 32 stocks experiencing net outflows, and 8 stocks seeing outflows exceeding 30 million yuan [1] - HaiTe Bio led the outflows with a net withdrawal of 79.69 million yuan, followed by YiPinHong, Chengdu XianDao, and BeiDa Pharmaceutical with outflows of 72.64 million yuan, 64.49 million yuan, and 52.64 million yuan respectively [1] Top Gainers and Losers - The top gainers in the recombinant protein sector included DeZhan Health, HuaXi Bio, and BoRui Pharmaceutical, with net inflows of 68.21 million yuan, 24.69 million yuan, and 17.58 million yuan respectively [3] - The detailed outflow list highlights stocks such as HaiTe Bio (-8.67%), YiPinHong (-2.70%), and Chengdu XianDao (-2.88%) as the most affected by capital withdrawal [2]

Group 1 - The core viewpoint of the news is that Sichuan Huiyu Pharmaceutical Co., Ltd. has experienced a decline in revenue and net profit in its latest quarterly report, indicating potential challenges in its financial performance [1][3]. - As of August 11, 2025, the stock price of Huiyu Pharmaceutical was 22.49 yuan, with a slight increase of 0.94% and a trading volume of 68,700 hands, amounting to a transaction value of 153 million yuan [1]. - The company reported total revenue of 239 million yuan for the first quarter of 2025, a year-on-year decrease of 1.46%, and a net profit attributable to shareholders of 25.63 million yuan, down 155.19% year-on-year [1]. Group 2 - The company has a current ratio of 3.409, a quick ratio of 3.189, and a debt-to-asset ratio of 20.27%, indicating a strong liquidity position [1]. - Sichuan Huiyu Pharmaceutical has made investments in 13 enterprises and participated in 697 bidding projects, showcasing its active engagement in the market [2]. - The company holds 373 trademark registrations and 136 patent applications, along with 109 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2].

Group 1 - The core point of the article is that Huili Pharmaceutical (688553) has filed an international patent application for a dual anti-cytokine fusion protein and its uses, with the application number PCT/CN2025/074454 and an international publication date of August 7, 2025 [1] Group 2 - Huili Pharmaceutical has announced a total of three international patent applications this year, which is a 25% decrease compared to the same period last year [2] - In the 2024 annual report, the company reported a research and development investment of 328 million yuan, reflecting a year-on-year decrease of 3.82% [2]